Yuli Ismartono

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.

MMV Medicines for Malaria Venture engages in the research, development, and discovery of antimalarial drugs. It focuses on developing medicines for case management, including patient-adapted new combinations to overcome drug resistance, to facilitate deployment of shorter treatment courses, and to protect vulnerable populations like children and pregnant women. The company was founded on November 3, 1999 and is headquartered in Geneva, Switzerland.